Pulmonx (NASDAQ:LUNG) General Counsel David Aaron Lehman Sells 14,334 Shares

Pulmonx Corporation (NASDAQ:LUNG) General Counsel David Lehman sold 14,334 shares of Pulmonx stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $2.26, for a total value of $32,394.84. Following the transaction, the general counsel owned 361,827 shares in the company, valued at $817,729.02. This trade represents a 3.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Pulmonx Price Performance

NASDAQ LUNG opened at $2.26 on Friday. The company has a debt-to-equity ratio of 0.95, a quick ratio of 3.52 and a current ratio of 4.32. The stock has a market cap of $97.07 million, a price-to-earnings ratio of -1.95 and a beta of 0.34. The business has a 50 day simple moving average of $1.81 and a 200 day simple moving average of $1.56. Pulmonx Corporation has a 52-week low of $1.13 and a 52-week high of $2.89.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings results on Wednesday, July 29th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. The firm had revenue of $22.76 million for the quarter, compared to analyst estimates of $22.39 million. Pulmonx had a negative net margin of 55.03% and a negative return on equity of 96.66%. Analysts anticipate that Pulmonx Corporation will post -1.05 earnings per share for the current fiscal year.

Key Stories Impacting Pulmonx

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Analysts maintain a generally favorable view of Pulmonx, with three Buy ratings and one Sell rating producing a “Moderate Buy” consensus and an average price target of $7.67. The company’s latest reported revenue of $22.76 million and loss of $0.24 per share also topped consensus estimates of $22.39 million and a $0.28-per-share loss. Pulmonx analyst and earnings information
• Neutral Sentiment: Four insiders—including CEO Glendon French III, General Counsel David Lehman, Geoffrey Rose and Srikanth Radhakrishnan—sold a combined 78,340 shares at approximately $2.26 per share. The filings state that the sales were made to cover tax-withholding obligations from vested equity awards, which reduces the likelihood that they signal a broad loss of confidence. The insiders still retain substantial holdings. Pulmonx insider sales report
• Neutral Sentiment: Institutional ownership remains high at approximately 91%, while several investment firms recently initiated small positions. These transactions may provide some ownership support but are not large enough, based on the available data, to materially change the near-term outlook. Pulmonx institutional ownership information
• Negative Sentiment: Recent gains appear to have prompted profit-taking, contributing to the stock’s retreat from its advance. Pulmonx shares fall following recent gains
• Negative Sentiment: Investor caution is heightened by Pulmonx’s “tepid” earnings outlook. The medical-device company remains loss-making, with analysts forecasting a full-year loss of approximately $1.05 per share, making sustained profitability and growth important catalysts for the stock. Pulmonx profit-taking and earnings outlook

Institutional Trading of Pulmonx

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. ADAR1 Capital Management LLC boosted its holdings in Pulmonx by 4.9% during the third quarter. ADAR1 Capital Management LLC now owns 214,497 shares of the company’s stock worth $347,000 after purchasing an additional 10,000 shares during the last quarter. Jain Global LLC grew its position in Pulmonx by 62.9% in the fourth quarter. Jain Global LLC now owns 30,566 shares of the company’s stock valued at $68,000 after purchasing an additional 11,800 shares in the last quarter. Cerity Partners LLC acquired a new stake in Pulmonx in the 4th quarter valued at $27,000. Algert Global LLC increased its stake in Pulmonx by 15.2% in the 2nd quarter. Algert Global LLC now owns 98,332 shares of the company’s stock valued at $128,000 after buying an additional 12,970 shares during the last quarter. Finally, Opal Capital LLC bought a new stake in Pulmonx during the 4th quarter worth about $29,000. 91.04% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have issued reports on LUNG shares. Weiss Ratings upgraded Pulmonx from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 25th. Wall Street Zen upgraded Pulmonx from a “sell” rating to a “hold” rating in a report on Saturday, June 27th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Pulmonx has an average rating of “Moderate Buy” and a consensus target price of $7.67.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.